CCN2 and idiopathic pulmonary fibrosis: Besides, neutralization of CTGF by pamrevlumab, a specific anti-CTGF monoclonal antibody, suppress TGF-β1-induced fibroblast proliferation and myofibroblast differentiation and mesothelial to mesenchymal transition in IPF [86].